Navigation Links
The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
Date:5/2/2013

EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United Kingdom), following the approval of its first biologic competitor—another TNF-alpha inhibitor—AbbVie/Eisai's Humira. According to the results of a survey conducted nearly one year after the European approval of Humira for ulcerative colitis, 69 percent of gastroenterologists pointed to Remicade as their most preferred biologic, while 27 percent of respondents indicated Humira.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The TreatmentTrends®: Ulcerative Colitis (EU) report finds that Remicade also leads over Humira in patient share estimates across the major European markets. While the new TNF-alpha inhibitor may not trail far behind Remicade in countries such as the United Kingdom and Germany, gastroenterologists from Italy and France provide estimates half those of Remicade. In addition to the relatively recent approval of Humira, physician perception of Humira's efficacy appears to be a factor limiting uptake as nearly one-third of European gastroenterologists noted its efficacy relative to Remicade as a disadvantage, but less than ten percent stated that its relative efficacy was an advantage. These findings may also explain Remicade's higher patient share compared with Humira in the severe segment (24 percent and 12 percent, respectively) that leads by a wider margin than in the moderate segment (11 percent and 7 percent, respectively).

The findings also reveal that approximately one-third of respondents were aware of new treatments in development for ulcerative colitis. After viewing product profiles of Takeda's vedolizumab, Janssen/Merck/Mitsubishi Tanabe's Simponi and Pfizer's tofacitinib, gastroenterologists reported a mean interest level for tofacitinib that is significantly greater than those of vedolizumab and Simponi. Additionally, tofacitinib received the greatest proportion of gastroenterologists identifying it as offering the most value to their practice. Oral administration was the most common reason given.

"However, when thinking of unmet needs for a new agent for moderate to severe UC, oral administration falls in the middle of the range of importance ratings among surveyed attributes, signaling that this attribute alone will not drive prescribing," said Decision Resources Group Senior Director Joanna Kim , M.Ed. "Efficacy will continue to be a key decision point."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com  


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
2. Allscripts adopts majority voting policy for directors
3. BD Completes Sale of Majority of Discovery Labware Unit
4. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
5. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
6. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
7. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
10. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
11. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/25/2017)... Spain and CAMBRIDGE, Massachusetts , ... Biotech, specializing in repurposing drugs to treat rare nervous system ... Inc. to clinically develop and market the drug SOM0226 against ... the drug achieved very promising results in a Phase 2 ... A new office in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... (ER) on Wednesday, August 16, to community partners. The newly renovated ER was ... Track” area for minor emergencies, eight semi-private rooms to deliver patient results, improve ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, ... trauma, to encourage inner healing of memories and achieve forgiveness, through a progressive ...
(Date:8/17/2017)... ... ... digital marketing for medical practices, has been recognized as one of the fastest growing privately ... second time in two years. Shawn Miele, Chief Executive Officer of Advice Media, said, “We ... a row. It’s extremely difficult to make this list once. The fact that we made ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun ... the season of sunshine. Add trying something new to this summer’s bucket list. Whether ... the fun. , Try Something New , Choose an activity the ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Ten outstanding teachers ... Stars in the Classroom and will win a visit by a Houston Texans player, ... who are at least five years old can visit texanschecking.com/stars to nominate their favorite ...
Breaking Medicine News(10 mins):